BUSINESS
Santen Aims to Net 400 Billion Yen in FY2029 Riding on Myopia, Droopy Eyelid Drugs
Santen Pharmaceutical has set out a revenue target of 400 billion yen for FY2029, up 100 billion yen versus FY2024, as it looks to double down on its efforts to push myopia and droopy eyelid treatments while extending its reach…
To read the full story
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





